AstraZeneca CEO: Explosive Q1 China Growth Will Ease In 2H, Then Reignite
Executive Summary
AstraZeneca generated 28% sales growth in China during the first quarter - but the UK group's CEO said that stellar performance will decline somewhat in the second half.